RBC raises target for Exelixis stock from USD 45 to USD 51

Published on 10/24/2026 at 21:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 10.60 percent to USD 628.69 million. Net profit reached USD 212.05 million, and Exelixis stock faces results October 29, 2026.

Analyst target and reporting date

RBC raised its Exelixis target from USD 45.00 to USD 51.00 on October 9, 2026.
Second-quarter revenue increased 10.60 percent to USD 628.69 million.
Exelixis stock last traded at USD 64.53 on October 23, 2026, down 1.19 percent from USD 65.31.
Exelixis will release third-quarter results on October 29, 2026.

EXEL, US30161Q1040, Illustration mit AI erstellt.

Exelixis (US30161Q1040) received a higher price target from RBC on October 9, 2026, with the firm lifting its target from USD 45.00 to USD 51.00 while keeping a Sector Perform rating, as MarketScreener reported. RBC's target lies 20.97 percent below the USD 64.53 Nasdaq price from October 23, 2026. Exelixis last traded at USD 64.53 on Nasdaq on October 23, 2026 at 4:00 p.m. EDT, down 1.19 percent from USD 65.31.

Revenue growth sets the backdrop

Exelixis reported second-quarter 2026 revenue of USD 628.69 million, up 10.60 percent from USD 568.26 million a year earlier. Net profit rose to USD 212.05 million from USD 184.85 million in the comparable quarter, according to The Globe and Mail. The revenue increase was therefore accompanied by a 14.73 percent rise in net profit.

Stock stays near its yearly high

As of October 23, 2026, Exelixis had a 52-week range of USD 36.00 to USD 65.50. The last price was 1.48 percent below the high and 79.25 percent above the low, while volume reached 2,066,166 shares. The stock's year-to-date performance stood at plus 47.23 percent.

Valuation and dates matter

Exelixis carried a market capitalization of USD 16.2 billion and a price-to-earnings ratio of 20.23 as of October 23, 2026. MarketScreener reported that the company will release third-quarter 2026 results on October 29, 2026, after the market close, followed by a conference call at 5:00 p.m. ET.

Comparison with peers

Exelixis: down 1.19 percent, P/E 20.23, market capitalization USD 16.2 billion. Gilead Sciences (Nasdaq, USD): down 0.73 percent, P/E minus 58.44, market capitalization USD 193.5 billion. Regeneron Pharmaceuticals (Nasdaq, USD): down 1.72 percent, P/E 19.91, market capitalization USD 82.9 billion.

Target revision meets a firm date

RBC's October 9 target revision gives investors a concrete valuation marker before the October 29 results. The latest quarter showed revenue growth of 10.60 percent, but the current Nasdaq price remains above the revised USD 51.00 target. The next earnings release will provide the next dated test of that gap.

The further course of trading is shown by the continuously updated real-time quote of Exelixis stock.